Ginkgo Bioworks Holdings Inc [NYSE: DNA] traded at a high on Thursday, posting a 12.15 gain after which it closed the day’ session at $8.31.
The results of the trading session contributed to over 3105454 shares changing hands. Over the past one week, the price volatility of Ginkgo Bioworks Holdings Inc stands at 12.91% while the volatility over the past one month is 10.50%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for DNA stock reached $436.94 million, with 38.13 million shares outstanding and 35.44 million shares in the current float. Compared to the average trading volume of 1.72M shares, DNA reached a trading volume of 3105454 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Ginkgo Bioworks Holdings Inc [DNA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $14.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 3.83. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Ginkgo Bioworks Holdings Inc shares, keeping their opinion on the stock as Sell, with their previous recommendation back on May 15, 2024. The new note on the price target was released on May 10, 2024, representing the official price target for Ginkgo Bioworks Holdings Inc stock. Previously, the target price had yet another drop from $3.50 to $2.50, while Raymond James kept a Mkt Perform rating on DNA stock.
The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc is set at 0.94, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 2.37. The Price to Book ratio for the last quarter was 0.49, with the Price to Cash per share for the same quarter was set at 13.94.
How has DNA stock performed recently?
Ginkgo Bioworks Holdings Inc [DNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.54. With this latest performance, DNA shares gained by 7.78% in over the last four-week period, additionally sinking by -81.93% over the last 6 months – not to mention a drop of -88.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 53.47, with the RSI for the last a single of trading hit 66.36, and the three-weeks RSI is set at 46.64 for Ginkgo Bioworks Holdings Inc [DNA]. The present Moving Average for the last 50 days of trading for this stock 9.83, while it was recorded at 7.02 for the last single week of trading, and 34.04 for the last 200 days.
Ginkgo Bioworks Holdings Inc [DNA]: Deeper insight into the fundamentals
Ginkgo Bioworks Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.71 and a Current Ratio set at 4.71.
Earnings analysis for Ginkgo Bioworks Holdings Inc [DNA]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ginkgo Bioworks Holdings Inc go to 31.20%.
Insider trade positions for Ginkgo Bioworks Holdings Inc [DNA]
There are presently around $63.84%, or 68.23%% of DNA stock, in the hands of institutional investors. The top three institutional holders of DNA stocks are: VIKING GLOBAL INVESTORS LP with ownership of 143.09 million shares, which is approximately 7.1383%. VANGUARD GROUP INC, holding 138.96 million shares of the stock with an approximate value of $$46.46 million in DNA stocks shares; and VANGUARD GROUP INC, currently with $$44.94 million in DNA stock with ownership which is approximately 6.7063%.
